CDMO News
Kedrion Biopharma Gains FDA Approval for RYPLAZIM Manufacturing in Italy
Kedrion Biopharma has announced that its manufacturing facility in Bolognana, Italy, has been approved by the U.S. Food and Drug Administration (FDA) to produce RYPLAZIM, a plasma-derived treatment for plasminogen deficiency type 1 (PLGD-1). This rare chronic condition primarily causes
22 November 2024